RAD-140 and LGD-4033 in 2026: Suppression, Lipids, and the PCT Myth Exposed

RAD-140 and LGD-4033 in 2026: Suppression, Lipids, and the PCT Myth Exposed

TL;DR- RAD-140 and LGD-4033 both suppress the HPT axis — the "no PCT needed" claim is clinically disproven.- LH, FSH, and free testosterone drop dose-dependently within three weeks on either compound.- HDL cholesterol falls 20–40% on SARMs — often worse than a moderate testosterone cycle.- A four-week mini-PCT with a SERM is the 2026 community standard after cycles exceeding six weeks.- "Selective" describes tissue preference, not a free pass from systemic side effects.- Blood panels before, during, and after every cycle are non-negotiable harm-reduction tools.

RAD-140 (Testolone) and LGD-4033 (Ligandrol) are non-steroidal selective androgen receptor modulators (SARMs) that preferentially activate the androgen receptor (AR) in skeletal muscle and bone tissue while exerting comparatively reduced activity in the prostate and skin. That tissue selectivity is real — but it has been consistently oversold as blanket safety. By August 2026, a meaningful body of Phase I clinical data, peer-reviewed pharmacokinetic studies, and community bloodwork aggregated across harm-reduction forums paints a clear picture: both compounds suppress the hypothalamic-pituitary-testicular (HPT) axis, both degrade the lipid profile, and both warrant structured post-cycle recovery. This article breaks down the mechanisms, the numbers, and the practical protocols.

How SARMs Bind the Androgen Receptor Differently

The AR is a nuclear receptor encoded by the AR gene on chromosome Xq11–12. Classical androgens — testosterone and DHT — activate it through full agonism, triggering transcription of anabolic target genes while also stimulating the prostate, accelerating androgenic alopecia via 5α-reductase conversion, and aromatising to oestradiol via CYP19A1.

SARMs exploit the concept of ligand-induced receptor conformational change. When RAD-140 or LGD-4033 binds the AR ligand-binding domain (LBD), it induces a slightly different helix-12 conformation compared to testosterone. This altered shape selectively recruits co-activator proteins (e.g., SRC-1, GRIP1) in muscle nuclei more efficiently than in prostate epithelium — the theoretical basis for selectivity. Neither compound is a substrate for 5α-reductase, so there is no DHT conversion. Neither aromatises via CYP19A1, so circulating oestradiol does not rise.

That last point is significant for two reasons: no oestrogen-driven water retention (a perceived benefit) and no oestrogen-driven HDL protection (a concrete risk, discussed below). The AR occupancy in the hypothalamus and pituitary, however, is sufficient to suppress gonadotropin-releasing hormone (GnRH) pulsatility and downregulate LH and FSH secretion — suppression is an inherent consequence of potent AR agonism anywhere in the body.

The Real Suppression Data: What Clinical Trials Show

The landmark Phase I trial of LGD-4033 published in the Journal of Gerontology (Basaria et al.) randomised healthy young men to doses of 0.1, 0.3, and 1.0 mg per day for 21 days. Even at the lowest clinical dose of 1 mg — a fraction of the 5–10 mg used in bodybuilding contexts — free testosterone, total testosterone, LH, FSH, and SHBG all fell in a statistically significant, dose-dependent manner. At 1 mg/day, free testosterone declined by approximately 50% from baseline. Recovery was observed within five weeks of cessation, but the study was only three weeks long at modest doses. Extrapolate to 10 mg for eight weeks and the suppression depth is considerably greater.

RAD-140 Phase I data (Myovant Sciences trial, later Radius Health) demonstrated comparable HPT axis suppression, with some analyses showing more pronounced testosterone reduction at equivalent molar doses — consistent with RAD-140's higher binding affinity for the AR relative to LGD-4033. Community bloodwork aggregated by harm-reduction platforms consistently shows that after six to eight weeks at 15–20 mg RAD-140, LH and FSH often fall below 1 IU/L and total testosterone drops below 200 ng/dL in a significant proportion of users.

The "no PCT required" narrative originated pre-2018, before widespread community bloodwork sharing, and it was never supported by clinical evidence. It is now considered misinformation in any credible evidence-based bodybuilding space.

Lipid Profile: The Overlooked Risk

Because SARMs do not aromatise, they produce no circulating oestradiol. This matters enormously for cardiovascular risk, because oestradiol is the primary driver of testosterone's HDL-raising and LDL-lowering effects. A testosterone replacement cycle at 200 mg/week modestly reduces HDL but simultaneously raises oestradiol, which partially offsets the lipid damage. SARMs offer no such offset.

Clinical and community data document HDL reductions of 20–40% on LGD-4033 and RAD-140, with LDL frequently rising in parallel. At higher doses (10 mg LGD-4033 or 20 mg RAD-140), the lipid disturbance can rival that of oral 17α-alkylated anabolic steroids — a comparison that surprises many users who assumed orals were categorically worse. The absence of hepatotoxic alkylation does not protect the lipid panel.

Practical implication: a fasted lipid panel is mandatory before starting any SARM cycle, at the midpoint of cycles exceeding eight weeks, and four weeks after the final dose. Users with baseline LDL above 130 mg/dL or HDL below 45 mg/dL should carefully reconsider the risk-benefit calculation before proceeding.

RAD-140 vs LGD-4033: A Practical Comparison

Both compounds have half-lives that allow once-daily dosing. RAD-140's shorter half-life means the gap between last dose and PCT initiation should be three to five days; LGD-4033's longer half-life warrants a five-to-seven-day washout before beginning a SERM.

The 2026 Mini-PCT Protocol: What the Evidence Supports

Post-cycle therapy for SARMs follows the same physiological rationale as for anabolic steroids: exogenous AR stimulation has suppressed GnRH pulsatility and downregulated pituitary LH/FSH production; the goal of a SERM is to block oestrogen negative feedback at the hypothalamus and pituitary, allowing the HPT axis to re-establish endogenous LH and FSH secretion, which in turn restores Leydig cell testosterone production.

The 2026 evidence-based community standard is:

• Enclomiphene 12.5–25 mg/day for four weeks, or
• Tamoxifen (Nolvadex) 10–20 mg/day for four weeks

Enclomiphene (the trans isomer of clomiphene) is preferred by many practitioners because it lacks the zuclomiphene isomer found in racemic clomiphene citrate, which has a longer half-life and can paradoxically worsen mood in some individuals. Tamoxifen remains a well-tolerated, accessible option with a long safety record in oncology literature.

Timing: begin PCT three to five days after the last RAD-140 dose, or five to seven days after the last LGD-4033 dose. Run for four full weeks. Obtain bloodwork — testosterone, LH, FSH, lipid panel, and ideally oestradiol — four weeks after completing PCT to confirm full recovery.

Short cycles (four to six weeks at low doses such as 5 mg LGD-4033 or 10 mg RAD-140) may recover without a formal SERM protocol, but bloodwork confirmation is still required. Guessing based on subjective energy levels is unreliable; suppression can persist asymptomatically.

Risks, Mitigation, and the Honest Risk-Benefit Balance

SARMs avoid several steroid-associated problems: no 5α-reduction means minimal scalp or prostate stimulation; no aromatisation means no gynaecomastia driven by oestrogen excess; no 17α-alkylation means lower direct hepatotoxicity risk (though isolated RAD-140 hepatotoxicity cases have been published in case report literature, likely reflecting product contamination or individual susceptibility).

What SARMs do not avoid: HPT suppression, HDL degradation, and the substantial risks associated with an unregulated research chemical market. Third-party assay data published by independent testing organisations consistently finds that a meaningful proportion of commercially available SARMs products are mislabelled, underdosed, overdosed, or contaminated with prohormones and other compounds. This product quality risk may represent the single largest practical danger for community users in 2026.

Honest risk stratification for 2026: a properly managed testosterone cycle at 250–300 mg/week is better characterised pharmacologically, more predictably dosed, and arguably better tolerated by many individuals than high-dose RAD-140. SARMs occupy a genuine niche — oral administration, reduced androgenic activity, moderate anabolic effect — but they are not the risk-free alternative their early marketing promised.

FAQ

Does LGD-4033 require PCT after a short four-week cycle?

At doses of 5 mg or below for four weeks or fewer, many users recover without a formal SERM protocol, but bloodwork is still essential to confirm this. At 10 mg for four weeks, suppression is documented and a four-week enclomiphene or tamoxifen protocol is recommended. Never substitute bloodwork with subjective energy assessment — suppression can be clinically present while symptoms remain mild.

Why do I feel fatigued and flat after stopping RAD-140?

Post-RAD-140 fatigue is the classic presentation of HPT axis suppression. RAD-140 produces no oestradiol (no aromatisation), so both testosterone and oestradiol fall simultaneously after cessation. Low oestradiol in men drives fatigue, low libido, and mood disruption as much as low testosterone does. A blood panel confirming suppression is the diagnostic step; a SERM-based mini-PCT is the evidence-supported intervention — not waiting it out.

Can I stack RAD-140 with testosterone base to avoid suppression symptoms?

Stacking RAD-140 with a low testosterone base (150–200 mg/week) prevents symptomatic suppression during the cycle by maintaining exogenous androgen status. It does not prevent HPT axis suppression — it replaces endogenous production rather than preserving it. PCT is still required after cycle cessation. Anyone already running injectable testosterone should critically evaluate whether adding a SARM provides a meaningful anabolic benefit over optimising the testosterone dose alone.

Are natural testosterone boosters effective as PCT alternatives after SARMs?

No. Tribulus terrestris, ZMA, D-aspartic acid, and ashwagandha have not demonstrated clinically meaningful gonadotropin stimulation in trials involving suppressed HPT axes. These compounds may support general wellbeing but do not replicate the SERM-mediated mechanism of blocking hypothalamic and pituitary oestrogen receptors to restore LH/FSH pulsatility. After documented suppression, only a SERM (or time, with confirmed bloodwork) represents evidence-based recovery.

Are RAD-140 and LGD-4033 legal to buy in the UK?

Neither compound is licensed as a medicine or approved as a supplement in the UK or EU. They are sold legally by some vendors as research chemicals, creating a regulatory grey area for personal possession. Both are prohibited in sport under WADA Code Category S1 (Anabolic Agents), meaning a positive test at any competitive level constitutes a doping violation. Legal status varies internationally and is subject to ongoing regulatory revision.

Conclusion

RAD-140 and LGD-4033 are pharmacologically meaningful compounds with legitimate tissue selectivity — but selectivity is not synonymous with safety, and the "SARMs need no PCT" myth has been definitively refuted by clinical data and community bloodwork alike. Anyone using either compound in 2026 should treat them as what they are: potent AR agonists that suppress the HPT axis, degrade the lipid profile, and require structured monitoring and post-cycle recovery. Blood panels, a four-week SERM protocol after cycles exceeding six weeks, and honest risk-benefit assessment against well-characterised alternatives are the cornerstones of responsible use.

This article is for educational harm-reduction purposes only and does not constitute medical advice. RAD-140 and LGD-4033 are unlicensed research substances with unknown long-term safety profiles. Consult a qualified healthcare professional before using any pharmacological compound.